4 Results for "

copanlisib

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "copanlisib" in MCE Product Catalog:

36
36 Publications Verification
Cat. No.: HY-15346
CAS No.: 1032568-63-0
Pureté:  99.50%
Synonyms: BAY 80-6946
Target:  

PI3K Apoptosis

Domaines de recherche:  

Cancer

Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
36
36 Publications Verification
Cat. No.: HY-15346A
CAS No.: 1402152-13-9
Pureté:  99.55%
Synonyms: BAY 80-6946 dihydrochloride
Target:  

PI3K Apoptosis

Domaines de recherche:  

Cancer

Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .
1
1 Cited Publications
Cat. No.: HY-15346R
CAS No.: 1032568-63-0
Synonyms: BAY 80-6946 (Standard)
Domaines de recherche:  

Cancer

Copanlisib (Standard) is the analytical standard of Copanlisib. This product is intended for research and analytical applications. Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
Cat. No.: HY-182086
CAS No.: 2355277-02-8
Domaines de recherche:  

Cancer

Copanlisib-NH is a PI3Kα/δ ligand. Copanlisib-NH can be used as a ligand for target protein for PROTAC to develop and design degraders of PROTAC PI3Kα/δ, such as PROTAC PI3Kα/δ degrader-1 (HY-182083). Copanlisib-NH can be used in breast cancer research .